Skip to content
Subscriber Only

Cytokinetics Amends ALS Therapy Trial After Mistake

Cytokinetics Inc., the developer of an experimental drug for amyotrophic lateral sclerosis, said it will increase the number of patients in a trial of the therapy after some were given a placebo by mistake.

After talking with regulators, Cytokinetics expanded the trial to include about 680 patients and updated the statistical methods section. The changes are expected to increase trial costs by about $5 million this year and next, the South San Francisco, California-based company said today in a statement.